Cellular experiments revealed that different FGFR2 genetic alterations promoted ICC tumor growth, invasion, and metastasis but responded differently to FGFR-selective small molecule kinase inhibitors (SMKIs). The gene discussed is FGFR2; the disease is intrahepatic cholangiocarcinoma.